News Related to Hypoplastic Left Heart Syndrome

Related coverage linked through entity extraction aliases.

Longeveron Phase 2b Trial Shows Stem Cell Therapy Improved Age-Related Frailty

Feb 26, 2026

Longeveron Inc. announced Phase 2b clinical trial results published in Cell Stem Cell showing laromestrocel improved physical condition in patients with age-related frailty after nine months compared to placebo.

Longeveron Appoints Stephen Willard as CEO Ahead of Pivotal HLHS Trial Results

Feb 14, 2026

Longeveron Inc. appointed Stephen H. Willard as CEO effective February 11, 2026, replacing interim CEO Than Powell. The appointment comes as the company expects top-line results from its pivotal Phase 2b trial for Hypoplastic Left Heart Syndrome in Q3 2026.